[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Biofire Defense\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":52},{"warningLetters":4,"total":51},[5,30],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},2200,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-02-21T14:20:00Z\">02\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-26T05:00:00Z\">01\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdesert-defense-llc-650718-01262023\">Desert Defense, LLC\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug Products","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Randall Thomason and Jane Laulis\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Desert Defense, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>31390 North 59th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cave Creek\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85331-3056\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@desertdefense.com\"> info@desertdefense.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 26, 2023\u003C\u002Fp>\n\n\u003Cp>Rogue Research, LLC\u003Cbr>\n4025 East Huntington Drive\u003Cbr>\nSuite 125\u003Cbr>\nFlagstaff, Arizona 85255\u003Cbr>\nUnited States\u003C\u002Fp>\n\n\u003Cp>Re: 650718\u003C\u002Fp>\n\n\u003Cp>Dear Randall Thomason and Jane Laulis:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s marketing of unapproved new animal drug products for the treatment of disease in animals, including but not limited to, “Desert Defense Original Formula, Yeast, Fungal &amp; Mold Support, and SuperBo Wellness Formula”. The U.S. Food and Drug Administration (FDA) has reviewed your website at the internet address www.desert-defense.com and www.rogueresearch.com\u002F in November and December 2022 and has determined that you distribute this product there. We have also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002FDesert.Defense.Valley.Fever\u002F where you direct consumers to your website at www.desert-defense.com to purchase products.\u003C\u002Fp>\n\n\u003Cp>Based on our review of your website and social media, your “Desert Defense” products are a drug under section 201(g)(1)(B) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)(1)(B)], because this product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. As explained further below, these products are an unapproved new animal drug and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>1. Examples of claims observed on your www.desert-defense.com website that show the intended uses of your “Desert Defense” products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From your website www.desert-defense.com: Webpage titled – “Desert Defense Dogs | A First Line of Defense Against Valley Fever for Your Dog”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“A First Line of Defense Against Valley Fever for Your Dog”\u003C\u002Fli>\n\t\u003Cli>“Desert Defense provides nutritional support for prevention or active cases of Valley Fever.”\u003C\u002Fli>\n\t\u003Cli>“Desert DEFENSE™ for Dogs was designed and tested to boost your dog’s natural defenses against the unique host of fungal, parasitic, viral and bacterial pathogens that flourish in the desert southwest.”\u003C\u002Fli>\n\t\u003Cli>“Desert DEFENSE™ | A Multi-Nutrient Formula For Dogs | A Holistic Defense Against | VALLEY FEVER | and other pathogenic invaders”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.desert-defense.com: Webpage titled – “Internet Orders | Desert Defense Dogs”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>Level 1: Original\u003C\u002Fstrong> – this is for dogs with active Valley Fever infections and can be used for preventative support but we prefer Level 2 for that. You may use this product with drugs with your vet’s approval and also as support to minimize the relapse cycle as your dog goes off drugs.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Level 2: Yeast, Fungal &amp; Mold Support\u003C\u002Fstrong> – this is for preventive support, mild to moderate cases of Valley Fever and intact canines. If you are visiting Arizona use this for support at lower doses for protection.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Level 3: SuperBotanical Wellness\u003C\u002Fstrong> – this is for dogs that are mature and have lived in the prime Valley Fever conditions without issues for year and senior pets. It is very mild.”\u003C\u002Fli>\n\t\u003Cli>“Desert Defense Original Formula $59.95 plus shipping 157 gm 5.5 oz Green label. This is our Original formula .... This formula is most appropriate for dogs that are sick and have lethargy as one of the issues. DD Original is our strongest formula. DD Original has been clinically tested and have been proven to reduce titers and symptoms in dogs suffering for Valley Fever.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.desert-defense.com: Webpage titled – “Desert Defense Dogs… Products”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>Level 1: Original\u003C\u002Fstrong> – this is for dogs with active Valley Fever infections and can be used for preventative support but we prefer Level 2 for that. You may use this product with drugs with your vet’s approval and also as support to minimize the relapse cycle as your dog goes off drugs.”\u003C\u002Fli>\n\t\u003Cli>“NEW PRODUCT: ORIGINAL STAGE 2 – The same strong product as Original but for dogs that do not have lethargy as an issue.”\u003C\u002Fli>\n\t\u003Cli>“Level 2: Yeast, Fungal &amp; Mold Support – this is for preventive support, mild to moderate cases of Valley Fever and intact canines. If you are visiting Arizona use this for support at lower doses for protection.”\u003C\u002Fli>\n\t\u003Cli>“Level 3: SuperBotanical Wellness – this is for dogs that are mature and have lived in the prime Valley Fever conditions without issue for years and senior pets. It is very mild.”\u003C\u002Fli>\n\t\u003Cli>“\u003Cstrong>ORGANIC ORIGINAL FORMULA \u003C\u002Fstrong>5.5 and 11 oz sizes | This is our Original formula …. This formula is most appropriate for dogs that are sick and have lethargy as one of the issues. DD Original is our strongest formula so we do not recommend this for maintenance. Instead use one or the other of the products listed above. DD Original has been clinically tested and has been proven to reduce titers and symptoms in dogs suffering from Valley Fever.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.desert-defense.com: Webpage titled – “FAQS &amp; BLOG | Desert Defense Dogs”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Postings on 12\u002F18\u002F12: Q: My dog has Valley Fever and my vet is recommending fluconazole. Is it safe to use your product? A: First always check with your veterinarian before introducing any supplementation in combination with a drug program. We did develop Desert Defense to be used in conjunction with fluconazole. In some cases it seems that it might greatly enhance the absorption of the drug. WE [sic] still always recommend a very slow loading period at small amounts to ensure no adverse reactions. We have had numerous reports from veterinarians and pet owners that the addition of Desert Defense vastly improved symptoms and titers.”\u003C\u002Fli>\n\t\u003Cli>\"Q: Does Desert Defense prevent Valley Fever? A: We developed this product as support for dogs with active cases of Valley Fever. It is virtually impossible for us to determine if it actually prevents Valley Fever… What we are trying to do is provide your dog as many tools as possible to keep a strong, sound immune system.”\u003C\u002Fli>\n\t\u003Cli>“Q: Should I use Sensitive or the Original formula for my dog? A: Initially we had one formula. … So the best recommendation is that if your dog is “sick” with Valley Fever please use the Original formula with your Veterinarian’s approval. If your dogs are exposed and carrying a titer then please use either Sensitive (now called Yeast, Fungal &amp; Mold Support) or our new SuperBo\u002FBasic formulas.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2. Examples of claims observed on your www.rogueresearch.com\u002F website that show the intended uses of your “Desert Defense” products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From your website www.rogueresearch.com: Webpage titled – “Rogue Research”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The First Line of Defense Against Valley Fever For Dogs!”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your website www.rogueresearch.com: Webpage titled – “Desert-Defense\u003Csup>TM\u003C\u002Fsup> for dogs..”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“A dietary supplement to support the endocrine, immune, digestive and detoxification functions of dogs that are exposed to coccidioidomycosis aka valley fever and other fungal, parasitic, viral and bacterial pathogens that flourish in the desert southwest.*”\u003C\u002Fli>\n\t\u003Cli>“Created for the potential to puncture lipid membranes of fungal cells”\u003C\u002Fli>\n\t\u003Cli>“Reduce inflammation”\u003C\u002Fli>\n\t\u003Cli>“Promote and deliver anti-fungal, anti-bacterial, and anti-viral activity”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>3. From your social media website www.facebook.com\u002FDesert.Defense.Valley.Fever: Webpage titled – “Desert Defense | Facebook”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your Facebook cover and profile photo states:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “Desert Defense\u003Csup>TM\u003C\u002Fsup> for dogs was designed and tested to boost your dogs natural defenses against the unique host of fungal, parasitic, viral, and bacterial pathogens that flourish in the desert southwest.”\u003Cbr>\n&nbsp; &nbsp; o “A First Line of Defense Against Valley Fever…”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On February 24, 2020 you posted: “…She cared for him 24\u002F7 and did research to find the best products to help him beat Valley Fever. One of the products she made sure he had every single day was Desert Defense!”\u003C\u002Fli>\n\t\u003Cli>Comment on post from October 13, 2019 – commenter states, “We have not have [sic] one dog get Valley Fever since we started using it as a preventative in 2014.” Your response: “… such great news – thank you!”\u003C\u002Fli>\n\t\u003Cli>On June 27, 2019 you posted: “…Desert Defense has kept all of our mastiffs free of Valley Fever all their lives. Can't do without it!\"\u003C\u002Fli>\n\t\u003Cli>On January 29, 2019 you posted: “This beautiful German Shorthaired Pointer lived to 15 years. ... When he was 8 he developed a Valley Fever titer and was placed on a holistic protocol based upon Desert Defense. He never went on any anti-fungal meds.”\u003C\u002Fli>\n\t\u003Cli>On January 29, 2016 you posted: “Important information: frequently when pets first start showing symptoms of Valley Fever they do not register a titer and thus the reason for misdiagnosis and the wrong course of treatment. If your pet is showing any signs then start Desert Defense while you await the diagnostics!”\u003C\u002Fli>\n\t\u003Cli>On October 24, 2017 you posted: “…He was diagnosed with giardia, eye infections, ear infections and valley fever. His titer was 1:256. His vet immediately put him on fluconazole and other meds for his eyes, ears, and stomach. We were unable to take him home until all but the valley fever had cleared up. On a recheck appointment with his vet, she suggested Desert Defense. … Another titer taken about a week ago showed he had gone from 1:256 to an amazing 1:32. We are certain, as is his vet, that the Desert Defense and his meds have made a tremendous difference and will continue with his treatments in the hope that he will someday not need them anymore.”\u003C\u002Fli>\n\t\u003Cli>On September 16, 2016 you posted: “Important information: Another veterinarian taking a dog off of anti-fungal drugs and using only Desert Defense and the results are astonishing. We are hearing from more and more pet parents that it's their veterinarian that recommends DD.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These products are new animal drugs, as defined by section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because they are not generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. They are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Therefore, the products are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action correct any violations. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of the receipt of this letter, please notify this office in writing of the steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent via e-mail to Dr. Vic Boddie at Vic.Boddie@fda.hhs.gov. If you have any questions or comments, please contact Dr. Boddie.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM, Director\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance &amp; Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nRandall Thomason and Jane Laulis\n\nDesert Defense, LLC\n\n31390 North 59th Street\n\nCave Creek, AZ 85331-3056\n\nUnited States\n\ninfo@desertdefense.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJanuary 26, 2023\n\nRogue Research, LLC\n\n4025 East Huntington Drive\n\nSuite 125\n\nFlagstaff, Arizona 85255\n\nUnited States\n\nRe: 650718\n\nDear Randall Thomason and Jane Laulis:\n\nThis letter concerns your firm’s marketing of unapproved new animal drug products for the treatment of disease in animals, including but not limited to, “Desert Defense Original Formula, Yeast, Fungal & Mold Support, and SuperBo Wellness Formula”. The U.S. Food and Drug Administration (FDA) has reviewed your website at the internet address www.desert-defense.com and www.rogueresearch.com\u002F in November and December 2022 and has determined that you distribute this product there. We have also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002FDesert.Defense.Valley.Fever\u002F where you direct consumers to your website at www.desert-defense.com to purchase products.\n\nBased on our review of your website and social media, your “Desert Defense” products are a drug under section 201(g)(1)(B) of the Federal Food Drug and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)(1)(B)], because this product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. As explained further below, these products are an unapproved new animal drug and introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\n1. Examples of claims observed on your www.desert-defense.com website that show the intended uses of your “Desert Defense” products include, but may not be limited to, the following:\n\nFrom your website www.desert-defense.com: Webpage titled – “Desert Defense Dogs | A First Line of Defense Against Valley Fever for Your Dog”\n\n“A First Line of Defense Against Valley Fever for Your Dog”\n\n“Desert Defense provides nutritional support for prevention or active cases of Valley Fever.”\n\n“Desert DEFENSE™ for Dogs was designed and tested to boost your dog’s natural defenses against the unique host of fungal, parasitic, viral and bacterial pathogens that flourish in the desert southwest.”\n\n“Desert DEFENSE™ | A Multi-Nutrient Formula For Dogs | A Holistic Defense Against | VALLEY FEVER | and other pathogenic invaders”\n\nFrom your website www.desert-defense.com: Webpage titled – “Internet Orders | Desert Defense Dogs”\n\n“Level 1: Original – this is for dogs with active Valley Fever infections and can be used for preventative support but we prefer Level 2 for that. You may use this product with drugs with your vet’s approval and also as support to minimize the relapse cycle as your dog goes off drugs.”\n\nLevel 2: Yeast, Fungal & Mold Support – this is for preventive support, mild to moderate cases of Valley Fever and intact canines. If you are visiting Arizona use this for support at lower doses for protection.”\n\nLevel 3: SuperBotanical Wellness – this is for dogs that are mature and have lived in the prime Valley Fever conditions without issues for year and senior pets. It is very mild.”\n\n“Desert Defense Original Formula $59.95 plus shipping 157 gm 5.5 oz Green label. This is our Original formula .... This formula is most appropriate for dogs that are sick and have lethargy as one of the issues. DD Original is our strongest formula. DD Original has been clinically tested and have been proven to reduce titers and symptoms in dogs suffering for Valley Fever.”\n\nFrom your website www.desert-defense.com: Webpage titled – “Desert Defense Dogs… Products”\n\n“Level 1: Original – this is for dogs with active Valley Fever infections and can be used for preventative support but we prefer Level 2 for that. You may use this product with drugs with your vet’s approval and also as support to minimize the relapse cycle as your dog goes off drugs.”\n\n“NEW PRODUCT: ORIGINAL STAGE 2 – The same strong product as Original but for dogs that do not have lethargy as an issue.”\n\n“Level 2: Yeast, Fungal & Mold Support – this is for preventive support, mild to moderate cases of Valley Fever and intact canines. If you are visiting Arizona use this for support at lower doses for protection.”\n\n“Level 3: SuperBotanical Wellness – this is for dogs that are mature and have lived in the prime Valley Fever conditions without issue for years and senior pets. It is very mild.”\n\n“ORGANIC ORIGINAL FORMULA 5.5 and 11 oz sizes | This is our Original formula …. This formula is most appropriate for dogs that are sick and have lethargy as one of the issues. DD Original is our strongest formula so we do not recommend this for maintenance. Instead use one or the other of the products listed above. DD Original has been clinically tested and has been proven to reduce titers and symptoms in dogs suffering from Valley Fever.”\n\nFrom your website www.desert-defense.com: Webpage titled – “FAQS & BLOG | Desert Defense Dogs”:\n\n“Postings on 12\u002F18\u002F12: Q: My dog has Valley Fever and my vet is recommending fluconazole. Is it safe to use your product? A: First always check with your veterinarian before introducing any supplementation in combination with a drug program. We did develop Desert Defense to be used in conjunction with fluconazole. In some cases it seems that it might greatly enhance the absorption of the drug. WE [sic] still always recommend a very slow loading period at small amounts to ensure no adverse reactions. We have had numerous reports from veterinarians and pet owners that the addition of Desert Defense vastly improved symptoms and titers.”\n\n\"Q: Does Desert Defense prevent Valley Fever? A: We developed this product as support for dogs with active cases of Valley Fever. It is virtually impossible for us to determine if it actually prevents Valley Fever… What we are trying to do is provide your dog as many tools as possible to keep a strong, sound immune system.”\n\n“Q: Should I use Sensitive or the Original formula for my dog? A: Initially we had one formula. … So the best recommendation is that if your dog is “sick” with Valley Fever please use the Original formula with your Veterinarian’s approval. If your dogs are exposed and carrying a titer then please use either Sensitive (now called Yeast, Fungal & Mold Support) or our new SuperBo\u002FBasic formulas.”\n\n2. Examples of claims observed on your www.rogueresearch.com\u002F website that show the intended uses of your “Desert Defense” products include, but may not be limited to, the following:\n\nFrom your website www.rogueresearch.com: Webpage titled – “Rogue Research”:\n\n“The First Line of Defense Against Valley Fever For Dogs!”\n\nFrom your website www.rogueresearch.com: Webpage titled – “Desert-DefenseTM for dogs..”:\n\n“A dietary supplement to support the endocrine, immune, digestive and detoxification functions of dogs that are exposed to coccidioidomycosis aka valley fever and other fungal, parasitic, viral and bacterial pathogens that flourish in the desert southwest.*”\n\n“Created for the potential to puncture lipid membranes of fungal cells”\n\n“Reduce inflammation”\n\n“Promote and deliver anti-fungal, anti-bacterial, and anti-viral activity”\n\n3. From your social media website www.facebook.com\u002FDesert.Defense.Valley.Fever: Webpage titled – “Desert Defense | Facebook”:\n\nYour Facebook cover and profile photo states:\n\no “Desert DefenseTM for dogs was designed and tested to boost your dogs natural defenses against the unique host of fungal, parasitic, viral, and bacterial pathogens that flourish in the desert southwest.”\n\no “A First Line of Defense Against Valley Fever…”\n\nOn February 24, 2020 you posted: “…She cared for him 24\u002F7 and did research to find the best products to help him beat Valley Fever. One of the products she made sure he had every single day was Desert Defense!”\n\nComment on post from October 13, 2019 – commenter states, “We have not have [sic] one dog get Valley Fever since we started using it as a preventative in 2014.” Your response: “… such great news – thank you!”\n\nOn June 27, 2019 you posted: “…Desert Defense has kept all of our mastiffs free of Valley Fever all their lives. Can't do without it!\"\n\nOn January 29, 2019 you posted: “This beautiful German Shorthaired Pointer lived to 15 years. ... When he was 8 he developed a Valley Fever titer and was placed on a holistic protocol based upon Desert Defense. He never went on any anti-fungal meds.”\n\nOn January 29, 2016 you posted: “Important information: frequently when pets first start showing symptoms of Valley Fever they do not register a titer and thus the reason for misdiagnosis and the wrong course of treatment. If your pet is showing any signs then start Desert Defense while you await the diagnostics!”\n\nOn October 24, 2017 you posted: “…He was diagnosed with giardia, eye infections, ear infections and valley fever. His titer was 1:256. His vet immediately put him on fluconazole and other meds for his eyes, ears, and stomach. We were unable to take him home until all but the valley fever had cleared up. On a recheck appointment with his vet, she suggested Desert Defense. … Another titer taken about a week ago showed he had gone from 1:256 to an amazing 1:32. We are certain, as is his vet, that the Desert Defense and his meds have made a tremendous difference and will continue with his treatments in the hope that he will someday not need them anymore.”\n\nOn September 16, 2016 you posted: “Important information: Another veterinarian taking a dog off of anti-fungal drugs and using only Desert Defense and the results are astonishing. We are hearing from more and more pet parents that it's their veterinarian that recommends DD.”\n\nThese products are new animal drugs, as defined by section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because they are not generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. They are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. Therefore, the products are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action correct any violations. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of the receipt of this letter, please notify this office in writing of the steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent via e-mail to Dr. Vic Boddie at Vic.Boddie@fda.hhs.gov. If you have any questions or comments, please contact Dr. Boddie.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM, Director\n\nDivision of Drug Compliance\n\nOffice of Surveillance & Compliance\n\nCenter for Veterinary Medicine","Desert Defense, LLC","desert-defense-llc-650718-01262023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdesert-defense-llc-650718-01262023","2026-10-26T08:08:23.496236+00:00","Warning Letter","Issued","2023-02-21","650718","Animal & Veterinary","Randall Thomason and Jane Laulis","2026-08-20T01:14:50.127+00:00","2023-01-26",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1009,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-12T04:00:00Z\">03\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwaxhead-sun-defense-company-688286-03122025\">Waxhead Sun Defense Company\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kari Kenner, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Shannon Kenner, CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Waxhead Sun Defense Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>614 Santa Maria Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fernandina Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32034\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mac@gowaxhead.com\"> mac@gowaxhead.com   \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 12, 2025\u003Cbr>\u003Cbr>\u003Cstrong>RE: 688286\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. and Mrs. Kenner:\u003C\u002Fp>\u003Cp>This letter is to advise you that in May 2024, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address https:\u002F\u002Fgowaxhead.com\u002F where your “Waxhead SUN DEFENSE SHAMPOO + CONDITIONER + BODY WASH + UV PROTECTION SUN DEFENSE BODY WASH with zinc oxide” (hereinafter “Waxhead Sun Defense Body Wash”) product is available for purchase in the United States without a prescription.\u003C\u002Fp>\u003Cp>Your “Waxhead Sun Defense Body Wash” product is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of the claims from the product labeling, including your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>“Scalp Sunscreen…Our Zinc Shampoo provides your hair and skin with daily UVA\u002FUVB\u002FUVC protection, creating a barrier against the sun's harsh rays…” [from your “Waxhead Sun Defense Body Wash” product website]\u003C\u002Fli>\u003Cli>Embrace the Waxhead Experience…∙ Boosts daily UVA\u002FUVB\u002FUVC protection: Safeguard your face, skin, and hair from incidental sun exposure.” [from your “Waxhead Sun Defense Body Wash” product website]\u003C\u002Fli>\u003Cli>“Waxhead Zinc Body Wash and Shampoo is the game-changer you've been waiting for…With our innovative scalp sunscreen and zinc body wash combination, you can effortlessly protect your skin from the sun's harmful rays without the need for sunscreen lotions…” [from your “Waxhead Sun Defense Body Wash” product website]\u003C\u002Fli>\u003Cli>“Added Layer of UV Protection… Our Zinc Body Wash and Shampoo boosts UV protection for the face, skin, and hair and helps protect areas difficult to cover with sunscreen, such as the scalp and ears.” [from your “Waxhead Sun Defense Body Wash” product website]\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Based on the above labeling, your “Waxhead Sun Defense Body Wash” is intended for use as an over-the-counter (OTC) sunscreen drug product. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for your drug product. Section 505G of the FD&amp;C Act, 21 U.S.C. 355h, governs the marketing of nonprescription drugs that are marketed without an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. 355, such as your product. Under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), a nonprescription drug is misbranded if the drug is subject to section 505G of the FD&amp;C Act, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>Section 505G of the FD&amp;C Act, 21 U.S.C. 355h, provides that certain nonprescription drugs are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if they, among other things, conform to the conditions in the applicable OTC monograph. In the case of OTC sunscreen drug products, the applicable OTC monograph is set forth in the final administrative order, OTC000006: Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020), which was deemed a final order by 505G(b)(8) and 505G(k)(2)(B).1,2 However, under section 505G(m)(2), “notwithstanding subsection [505G](a),” sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder may only be lawfully marketed, without an application approved under section 505 of the FD&amp;C Act, pursuant to an order issued under section 505G of the FD&amp;C Act.3 To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing of sunscreen in a shampoo or face\u002Fbody wash dosage form. As previously stated, there is no FDA-approved application in effect for your drug product.\u003C\u002Fp>\u003Cp>Thus, even if your product were in conformity with the conditions set forth in M020 and all other applicable requirements to be deemed GRASE and not a new drug under section 505G(a)(1), it does not comply with the requirements under section 505G. Accordingly, your “Waxhead Sun Defense Body Wash” sunscreen drug product is a misbranded drug introduced or delivered for introduction into interstate commerce in violation of sections 502(ee) and 301(a) of the FD&amp;C Act, 21 U.S.C. 352(ee) and 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See sections 505G(a)(1) and (2) of the FD&amp;C Act and see Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf. As required by section 505G(a)(2), M020 encompasses the requirements specified in part 352 of title 21, Code of Federal Regulations, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in section 201.327 of title 21, Code of Federal Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your “Waxhead Sun Defense Body Wash” also appears to include intended uses as an antifungal, for the control of dandruff and psoriasis, and for acne. OTC antifungal drug products, dandruff and psoriasis drug products, and acne drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in their respective final administrative orders: Over-the-Counter Monograph M005: Topical Antifungal Drug Products for Over-the-Counter Human Use; Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use; and Over-the-Counter Monograph M006: Topical Acne Drug Products for Over-the-Counter Human Use, respectively. There are no provisions in any of the respective categories’ monographs, nor any monograph, that allow for a combination sunscreen, antifungal, control of dandruff and psoriasis, and acne drug product.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(m)(2) provides that “[n]otwithstanding subsection [505G](a),” a drug that, “prior to the date of the enactment of this section [March 27, 2020], the Secretary determined in a proposed or final rule to be ineligible for review under the OTC drug review” (emphasis added) may not be legally marketed without an approved NDA or ANDA except as “pursuant to an order issued under this section”. In a 2019 proposed rule, FDA determined that sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder were ineligible for review under the OTC Drug Review under the then-operative requirements because we did not receive data showing that they were marketed prior to 1972. 84 FR 6024 at 6229-6230 (Feb. 26, 2019); see also 84 FR 6024 at 6206 and 6272. Therefore, under section 505G(m)(2) of the FD&amp;C Act, a sunscreen in any dosage form other than the ten dosage forms listed above may only be marketed with an approved application, unless FDA determines otherwise in an order issued under section 505G of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nKari Kenner, CEO\n\nRecipient Title\n\nShannon Kenner, CEO\n\nWaxhead Sun Defense Company\n\n614 Santa Maria Dr\n\nFernandina Beach, FL 32034\n\nUnited States\n\nmac@gowaxhead.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 12, 2025\n\nRE: 688286\nDear Mr. and Mrs. Kenner:\nThis letter is to advise you that in May 2024, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address https:\u002F\u002Fgowaxhead.com\u002F where your “Waxhead SUN DEFENSE SHAMPOO + CONDITIONER + BODY WASH + UV PROTECTION SUN DEFENSE BODY WASH with zinc oxide” (hereinafter “Waxhead Sun Defense Body Wash”) product is available for purchase in the United States without a prescription.\nYour “Waxhead Sun Defense Body Wash” product is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\nExamples of the claims from the product labeling, including your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n“Scalp Sunscreen…Our Zinc Shampoo provides your hair and skin with daily UVA\u002FUVB\u002FUVC protection, creating a barrier against the sun's harsh rays…” [from your “Waxhead Sun Defense Body Wash” product website]\nEmbrace the Waxhead Experience…∙ Boosts daily UVA\u002FUVB\u002FUVC protection: Safeguard your face, skin, and hair from incidental sun exposure.” [from your “Waxhead Sun Defense Body Wash” product website]\n“Waxhead Zinc Body Wash and Shampoo is the game-changer you've been waiting for…With our innovative scalp sunscreen and zinc body wash combination, you can effortlessly protect your skin from the sun's harmful rays without the need for sunscreen lotions…” [from your “Waxhead Sun Defense Body Wash” product website]\n“Added Layer of UV Protection… Our Zinc Body Wash and Shampoo boosts UV protection for the face, skin, and hair and helps protect areas difficult to cover with sunscreen, such as the scalp and ears.” [from your “Waxhead Sun Defense Body Wash” product website]\nBased on the above labeling, your “Waxhead Sun Defense Body Wash” is intended for use as an over-the-counter (OTC) sunscreen drug product. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for your drug product. Section 505G of the FD&C Act, 21 U.S.C. 355h, governs the marketing of nonprescription drugs that are marketed without an approved application under section 505 of the FD&C Act, 21 U.S.C. 355, such as your product. Under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), a nonprescription drug is misbranded if the drug is subject to section 505G of the FD&C Act, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nSection 505G of the FD&C Act, 21 U.S.C. 355h, provides that certain nonprescription drugs are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if they, among other things, conform to the conditions in the applicable OTC monograph. In the case of OTC sunscreen drug products, the applicable OTC monograph is set forth in the final administrative order, OTC000006: Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020), which was deemed a final order by 505G(b)(8) and 505G(k)(2)(B).1,2 However, under section 505G(m)(2), “notwithstanding subsection [505G](a),” sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder may only be lawfully marketed, without an application approved under section 505 of the FD&C Act, pursuant to an order issued under section 505G of the FD&C Act.3 To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing of sunscreen in a shampoo or face\u002Fbody wash dosage form. As previously stated, there is no FDA-approved application in effect for your drug product.\nThus, even if your product were in conformity with the conditions set forth in M020 and all other applicable requirements to be deemed GRASE and not a new drug under section 505G(a)(1), it does not comply with the requirements under section 505G. Accordingly, your “Waxhead Sun Defense Body Wash” sunscreen drug product is a misbranded drug introduced or delivered for introduction into interstate commerce in violation of sections 502(ee) and 301(a) of the FD&C Act, 21 U.S.C. 352(ee) and 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________\n1 See sections 505G(a)(1) and (2) of the FD&C Act and see Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf. As required by section 505G(a)(2), M020 encompasses the requirements specified in part 352 of title 21, Code of Federal Regulations, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in section 201.327 of title 21, Code of Federal Regulations.\n2 We note that your “Waxhead Sun Defense Body Wash” also appears to include intended uses as an antifungal, for the control of dandruff and psoriasis, and for acne. OTC antifungal drug products, dandruff and psoriasis drug products, and acne drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in their respective final administrative orders: Over-the-Counter Monograph M005: Topical Antifungal Drug Products for Over-the-Counter Human Use; Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use; and Over-the-Counter Monograph M006: Topical Acne Drug Products for Over-the-Counter Human Use, respectively. There are no provisions in any of the respective categories’ monographs, nor any monograph, that allow for a combination sunscreen, antifungal, control of dandruff and psoriasis, and acne drug product.\n3 Section 505G(m)(2) provides that “[n]otwithstanding subsection [505G](a),” a drug that, “prior to the date of the enactment of this section [March 27, 2020], the Secretary determined in a proposed or final rule to be ineligible for review under the OTC drug review” (emphasis added) may not be legally marketed without an approved NDA or ANDA except as “pursuant to an order issued under this section”. In a 2019 proposed rule, FDA determined that sunscreens in all dosage forms other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder were ineligible for review under the OTC Drug Review under the then-operative requirements because we did not receive data showing that they were marketed prior to 1972. 84 FR 6024 at 6229-6230 (Feb. 26, 2019); see also 84 FR 6024 at 6206 and 6272. Therefore, under section 505G(m)(2) of the FD&C Act, a sunscreen in any dosage form other than the ten dosage forms listed above may only be marketed with an approved application, unless FDA determines otherwise in an order issued under section 505G of the FD&C Act.","Waxhead Sun Defense Company","waxhead-sun-defense-company-688286-03122025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwaxhead-sun-defense-company-688286-03122025","2026-10-26T08:10:30.819728+00:00","2025-03-18","688286","Drugs Over-the-Counter Drugs","Kari Kenner, CEO","2026-08-19T16:57:05.337+00:00","2025-03-12",2,{"510k":53,"classification":54,"enforcement":55,"event":56,"event_backfill":57,"pma":58,"warning_letter":59},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]